Answers are grounded in this paper and cite their sources.
Preclinical study reveals dual targeting of copper delivery and iron-sulfur homeostasis triggers cuproptosis in cancer cells, highlighting a strategy to overcome therapy resistance.
Cellular resilience to therapy often arises from adaptive mechanisms that safeguard iron–sulfur (Fe–S) proteins. Here, we present a rational strategy to overcome such resilience by integrating two synergistic vulnerabilities, copper toxicity and Fe–S cluster homeostasis, into a single molecular scaffold. Inspired by a bacterial sulfur mobilization (SUF) inhibitor, we hybridized its core structure with a copper-transporting 8-hydroxyquinoline moiety to generate HDQ, HDQ-S, HDQ-Ph, and HDQ-Me. They coordinate copper via hydroxyquinoline and efficiently transport copper into cancer cells, with HDQ-Me achieving an efficacy comparable to that of the clinical copper ionophore elesclomol (ES). Strikingly, HDQ alone suppresses Fe–S proteins across multiple functions, including respiration, iron homeostasis, and DNA replication. HDQ-mediated copper loading triggers cuproptosis hallmarks, DNA damage, and ATP collapse, generating a synergistic lethality. This work establishes HDQs as bifunctional tools that cotarget copper and Fe–S protein homeostasis, validating a convergent therapeutic strategy against resilient cells.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: